Patents by Inventor Helene Derand
Helene Derand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240398769Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.Type: ApplicationFiled: August 15, 2024Publication date: December 5, 2024Applicant: XSPRAY PHARMA ABInventors: Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
-
Patent number: 12144804Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.Type: GrantFiled: July 22, 2024Date of Patent: November 19, 2024Assignee: XSPRAY PHARMA ABInventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
-
Publication number: 20240374577Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.Type: ApplicationFiled: July 22, 2024Publication date: November 14, 2024Applicant: XSPRAY PHARMA ABInventors: Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
-
Patent number: 12076314Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.Type: GrantFiled: January 12, 2024Date of Patent: September 3, 2024Assignee: XSPRAY PHARMA ABInventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
-
Publication number: 20240189290Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.Type: ApplicationFiled: January 12, 2024Publication date: June 13, 2024Applicant: XSPRAY PHARMA ABInventors: Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
-
Patent number: 11963951Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.Type: GrantFiled: December 16, 2021Date of Patent: April 23, 2024Assignee: XSPRAY PHARMA ABInventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
-
Patent number: 11517562Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.Type: GrantFiled: June 1, 2022Date of Patent: December 6, 2022Assignee: XSPRAY PHARMA ABInventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
-
Publication number: 20220296575Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.Type: ApplicationFiled: June 1, 2022Publication date: September 22, 2022Applicant: XSPRAY PHARMA ABInventors: Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
-
Patent number: 11426391Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.Type: GrantFiled: February 14, 2022Date of Patent: August 30, 2022Assignee: XSPRAY PHARMA ABInventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
-
Patent number: 11376243Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.Type: GrantFiled: February 14, 2022Date of Patent: July 5, 2022Assignee: XSPRAY PHARMA ABInventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
-
Publication number: 20220168285Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.Type: ApplicationFiled: February 14, 2022Publication date: June 2, 2022Applicant: XSPRAY PHARMA ABInventors: Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
-
Publication number: 20220160687Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.Type: ApplicationFiled: February 14, 2022Publication date: May 26, 2022Applicant: XSPRAY PHARMA ABInventors: Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
-
Publication number: 20220117947Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.Type: ApplicationFiled: December 16, 2021Publication date: April 21, 2022Applicant: XSPRAY PHARMA ABInventors: Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
-
Patent number: 11241419Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.Type: GrantFiled: August 18, 2020Date of Patent: February 8, 2022Assignee: XSPRAY PHARMA ABInventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
-
Publication number: 20210093616Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.Type: ApplicationFiled: August 18, 2020Publication date: April 1, 2021Applicant: XSPRAY MICROPARTICLES ABInventors: Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
-
Patent number: 10772877Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.Type: GrantFiled: February 7, 2020Date of Patent: September 15, 2020Assignee: XSPRAY MICROPARTICLES ABInventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
-
Publication number: 20200253941Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.Type: ApplicationFiled: February 7, 2020Publication date: August 13, 2020Applicant: XSPRAY MICROPARTICLES ABInventors: Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
-
Patent number: 10561645Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.Type: GrantFiled: May 6, 2019Date of Patent: February 18, 2020Assignee: XSPRAY MICROPARTICLES ABInventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
-
Patent number: 10561644Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.Type: GrantFiled: May 6, 2019Date of Patent: February 18, 2020Assignee: XSPRAY MICROPARTICLES ABInventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
-
Patent number: 10561643Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.Type: GrantFiled: May 6, 2019Date of Patent: February 18, 2020Assignee: XSPRAY MICROPARTICLES ABInventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand